Invention Grant
- Patent Title: Therapeutic antibodies binding IL12Rβ1
- Patent Title (中): 治疗性抗体结合IL12R＆bgr; 1
-
Application No.: US13265346Application Date: 2010-03-29
-
Publication No.: US08715657B2Publication Date: 2014-05-06
- Inventor: Michael Bardroff , Jose M. Carballido Herrera , Daniela Della Ducata , Christoph Heusser , Ute Jaeger , Christoph Schwaerzler
- Applicant: Michael Bardroff , Jose M. Carballido Herrera , Daniela Della Ducata , Christoph Heusser , Ute Jaeger , Christoph Schwaerzler
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Karen A. Lacourse
- International Application: PCT/EP2010/054093 WO 20100329
- International Announcement: WO2010/112458 WO 20101007
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/00 ; C12P21/08 ; C12P21/04 ; C12N15/00 ; C12N5/02 ; C07H21/04
Abstract:
The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
Public/Granted literature
- US20120034231A1 COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES Public/Granted day:2012-02-09
Information query
